Next Article in Journal
Prader-Willi Syndrome and Schaaf-Yang Syndrome: Neurodevelopmental Diseases Intersecting at the MAGEL2 Gene
Next Article in Special Issue
Targeted Therapy of Hepatitis B Virus-Related Hepatocellular Carcinoma: Present and Future
Previous Article in Journal
Puzzle Pieces: Neural Structure and Function in Prader-Willi Syndrome
Previous Article in Special Issue
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future
Article Menu

Export Article

Open AccessReview
Diseases 2016, 4(1), 1; doi:10.3390/diseases4010001

Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy

University of Pittsburgh Medical Center, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, 5150 Center Ave. 5th floor, Pittsburgh, PA 15232, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen L. Chan
Received: 2 October 2015 / Revised: 3 December 2015 / Accepted: 16 December 2015 / Published: 25 December 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
View Full-Text   |   Download PDF [263 KB, uploaded 25 December 2015]

Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer related mortality worldwide. The incidence of HCC has been increasing annually. Viral infection, alcohol usage, and other causes of cirrhosis have been identified as major risk factors for HCC development. The underlying pathogenesis has not been as well defined. There have been multiple hypotheses to the specific mechanisms of hepatocarcinogenesis and they share the common theme of chronic inflammation, increase oxidative stress, and genomic alteration. Therapeutic options of HCC have been primarily local and/or regional including transplantation, resection, and radial frequency ablation, chemoembolization or radio-embolization. For unresectable or metastatic disease, the options are limited. Conventional chemotherapeutic options have been noted to have limited benefit. Sorafenib has been the one and only systemic therapy which has demonstrated modest overall survival benefit. This has led to more extensive research with focus on targeted therapy. Numerous pre-clinical and early phase clinical studies have been noted but failed to show efficacy in later phase clinical trials. In an effort to identify new potential therapeutic options, new understanding of underlying pathways to hepatocarcinogenesis should be one of the main focuses. This leads to development of more molecularly targeted agents to specific pathways, and immunotherapy. This article provides a review of major studies of molecular targeted agents which attempts to target these specific pathways in HCC. View Full-Text
Keywords: hepatocellular carcinoma; HCC; molecular therapy; targeted therapy; immunotherapy; sorafenib hepatocellular carcinoma; HCC; molecular therapy; targeted therapy; immunotherapy; sorafenib
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Nguyen, K.; Jack, K.; Sun, W. Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy. Diseases 2016, 4, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top